Skip to main content
SpringerLink
Log in

Testing non-US born residents for latent TB cost effective

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Tasillo A, et al. Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model. JAMA Internal Medicine : 16 Oct 2017. Available from: URL: http://dx.doi.org/10.1001/jamainternmed.2017.3941.

  2. Flood J, et al. Mainstreaming Latent Tuberculosis Infection Testing and Treatment in the United States. Who and How. JAMA Internal Medicine : 16 Oct 2017. Available from: URL: http://dx.doi.org/10.1001/jamainternmed.2017.4916.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Testing non-US born residents for latent TB cost effective. PharmacoEcon Outcomes News 790, 31 (2017). https://doi.org/10.1007/s40274-017-4476-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4476-8

Search

Navigation